Fractures, Other Skeletal Issues Lead to High Postdischarge Costs in Patients With MM, Bone Metastases

December 23rd 2020, 9:35pm


Most patients with bone metastases or multiple myeloma (MM) who are hospitalized with skeletal-related events require lengthy and costly follow-up care after they are discharged.

Rolling Submission Begins for BLA on Cilta-Cel in R/R Multiple Myeloma

December 21st 2020, 2:30pm


Results presented earlier this month at ASH showed a 97% overall response rate, and progression-free survival had not been reached.

Multiple Myeloma Therapy on Cusp of New Era, but Much Is Left to Prove, Review Says

December 17th 2020, 9:45pm


Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.

BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds

December 16th 2020, 11:15am


A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.

Tumor Lysis Syndrome Risk May Rise With Use of Bortezomib for MM in Men

December 11th 2020, 2:00pm


The research raises the possibility that the type of therapy used can increase the risk of tumor lysis syndrome from low to moderate in men with multiple myeloma (MM).

Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma

December 9th 2020, 10:15pm


The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.

Study Examines Trends in Mortality Rates of Multiple Myeloma in US Adults

December 4th 2020, 4:23pm


The United States is becoming older, more diverse, and more overweight, and these changes may influence future trends in certain hematological cancers.

Considerations for Designing ePRO Interventions for Patients With RRMM

December 4th 2020, 3:24pm


Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).

Review Examines New Options for Patients With Aplastic Anemia

November 28th 2020, 11:15am


Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope.

Real-World Data Confirm KRd Safety, Efficacy in RRMM

November 26th 2020, 12:30pm


New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.